Altimmune Inc (ALT)

$5.47 -0.08 (-1.44%)
Market Cap 631.87M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.08
Volume 4,563,700
Avg Vol 5,313,538
Day's Range N/A - N/A
Shares Out 112.83M
Stochastic %K 46%
Beta 0.04
Analysts Strong Sell
Price Target $17.78

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
TheCowboy
TheCowboy Feb. 4 at 6:44 AM
$ALT
0 · Reply
Excessive_
Excessive_ Feb. 4 at 6:34 AM
$ALT Looks like our troll is on a bender again.🤣
0 · Reply
Stock_Australopithecus
Stock_Australopithecus Feb. 4 at 6:12 AM
$ALT me when I invest in Alt for three straight years
0 · Reply
BioRich
BioRich Feb. 4 at 6:05 AM
$ALT @Designed2Gain If you believe what I post is Doubt, it's because $ALT past performance was underwhelming and their future carries a lot of doubt. That's not me sharing anything other than the reality about a clinical stage biotech with $ALT's performance.
0 · Reply
BioRich
BioRich Feb. 4 at 6:03 AM
$ALT @Designed2Gain If you believe what I post is Uncertainty, then it's admission of $ALT not doing what's best for shareholders and keeping them abreast of critical company happenings.
0 · Reply
BioRich
BioRich Feb. 4 at 6:00 AM
$ALT @Designed2Gain If you believe what I post is Fear, then it's a reality that there's reason for concern with $ALT. I share truth. You realize that's how that works right? Typical $ALT #27Dresses #BadJab #JimmyHeartsBadBunny #LossOfTrialControl #PoorDataIntegrity #CompulsiveLies #Gullible
0 · Reply
BioRich
BioRich Feb. 4 at 5:24 AM
$GUTS It's funny watching the low lifes from the $ALT board come over and talk crap on things they don't know about. Looking at Bearish messages, they are basically all pukes from the cancerous $ALT board. Kind of gives us strength in a way. As for this ill-advised comment, "next gen pills", they are basically lesser GLP-1s that still require the same regimen and same AEs. The market for weight loss retention is huge and I still see $GUTS as being a leader (if not the leader). Time and more trials will help prove this. Cheers!
0 · Reply
Cjs2027
Cjs2027 Feb. 4 at 5:19 AM
$ALT i reiterate my belief that GIA is probably not on Durso’s plans.
1 · Reply
HansWurst19
HansWurst19 Feb. 4 at 4:58 AM
$ALT quick question cuz I cannot follow up on posts and replies. Where does March 13 deadline come from and what will be dead afterwards? Thanks
1 · Reply
StockDark
StockDark Feb. 4 at 4:36 AM
$ALT Three binary events that must resolve in the next 38 days and chances of re-rating. 1) Whale reveal(new fundamental institutional investor), 2) Short squeeze friction, 3) EMA De-risking news.
1 · Reply
Latest News on ALT
Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 12 hours ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 29, 2026, 5:54 PM EST - 5 days ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Jan 28, 2026, 4:13 PM EST - 6 days ago

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 27, 2026, 9:25 PM EST - 7 days ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Jan 5, 2026, 7:30 AM EST - 4 weeks ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Dec 23, 2025, 7:42 PM EST - 6 weeks ago

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Dec 19, 2025, 12:57 PM EST - 6 weeks ago

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Dec 19, 2025, 11:37 AM EST - 6 weeks ago

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:42 AM EST - 6 weeks ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 19, 2025, 6:30 AM EST - 6 weeks ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 2 months ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 2 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 3:03 PM EST - 2 months ago

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 2 months ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 3 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 3 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 3 months ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 3 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 3 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 3 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 4 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 4 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 4 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 4 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 5 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 5 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 5 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 5 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 6 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 6 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

TheCowboy
TheCowboy Feb. 4 at 6:44 AM
$ALT
0 · Reply
Excessive_
Excessive_ Feb. 4 at 6:34 AM
$ALT Looks like our troll is on a bender again.🤣
0 · Reply
Stock_Australopithecus
Stock_Australopithecus Feb. 4 at 6:12 AM
$ALT me when I invest in Alt for three straight years
0 · Reply
BioRich
BioRich Feb. 4 at 6:05 AM
$ALT @Designed2Gain If you believe what I post is Doubt, it's because $ALT past performance was underwhelming and their future carries a lot of doubt. That's not me sharing anything other than the reality about a clinical stage biotech with $ALT's performance.
0 · Reply
BioRich
BioRich Feb. 4 at 6:03 AM
$ALT @Designed2Gain If you believe what I post is Uncertainty, then it's admission of $ALT not doing what's best for shareholders and keeping them abreast of critical company happenings.
0 · Reply
BioRich
BioRich Feb. 4 at 6:00 AM
$ALT @Designed2Gain If you believe what I post is Fear, then it's a reality that there's reason for concern with $ALT. I share truth. You realize that's how that works right? Typical $ALT #27Dresses #BadJab #JimmyHeartsBadBunny #LossOfTrialControl #PoorDataIntegrity #CompulsiveLies #Gullible
0 · Reply
BioRich
BioRich Feb. 4 at 5:24 AM
$GUTS It's funny watching the low lifes from the $ALT board come over and talk crap on things they don't know about. Looking at Bearish messages, they are basically all pukes from the cancerous $ALT board. Kind of gives us strength in a way. As for this ill-advised comment, "next gen pills", they are basically lesser GLP-1s that still require the same regimen and same AEs. The market for weight loss retention is huge and I still see $GUTS as being a leader (if not the leader). Time and more trials will help prove this. Cheers!
0 · Reply
Cjs2027
Cjs2027 Feb. 4 at 5:19 AM
$ALT i reiterate my belief that GIA is probably not on Durso’s plans.
1 · Reply
HansWurst19
HansWurst19 Feb. 4 at 4:58 AM
$ALT quick question cuz I cannot follow up on posts and replies. Where does March 13 deadline come from and what will be dead afterwards? Thanks
1 · Reply
StockDark
StockDark Feb. 4 at 4:36 AM
$ALT Three binary events that must resolve in the next 38 days and chances of re-rating. 1) Whale reveal(new fundamental institutional investor), 2) Short squeeze friction, 3) EMA De-risking news.
1 · Reply
MilkStar
MilkStar Feb. 4 at 4:31 AM
$ALT tomorrow will be a beautiful day 🎉🎉🎉🎉🎉🎉🎉
0 · Reply
StockDark
StockDark Feb. 4 at 4:26 AM
$ALT shorts are in a dangerous spot here. If they are still short on March 13, they do not have voting rights. Many institutional lenders will recall their shares from shorts before the record date so they can vote themselves, which can trigger a squeeze. Ofcourse, you never know what other tricks MM and Durso will play to save the shorts.
0 · Reply
ItIsGoTime
ItIsGoTime Feb. 4 at 4:15 AM
$ALT good read. It covers almost everything, except the Lacert late-break oral & poster presentations. Thanks for sharing.
1 · Reply
Chucho64
Chucho64 Feb. 4 at 4:08 AM
$ALT ALT Benefits Date Benefits Announcement* for ALT Feb 26, 2026🤔🤔🤔
0 · Reply
LeaperM75
LeaperM75 Feb. 4 at 3:54 AM
$ALT What are your thoughts on that Seeking Alpha article I posted? See below a few posts down for full article slides.
3 · Reply
KCWTX
KCWTX Feb. 4 at 3:52 AM
$ALT If there is a buyout or partnership, basis on the March 13 record date in 8k, for that date to be legally and strategically valid for a transactional vote, the announcement will have to be made before Feb 16/17. My logical bet is between Feb 9-13. Feb 16 is President Day.
1 · Reply
Chucho64
Chucho64 Feb. 4 at 3:49 AM
$ALT They're not going to go it alone; it's not feasible. If they're asking for a lot of money for a back office, then they should partner up first, and once they have the results, they should sell.💯💯💯💯💯💯💯💥
1 · Reply
StockDark
StockDark Feb. 4 at 3:35 AM
$ALT US-Ready(BTD), EU-Ready(waiting for confirmation), Cash-Ready, Board-Ready. Everything is converging on that April 16 date. If a buyout is going to happen, the data room review by big pharma will likely conclude once the EMA alignment is confirmed.(Not sure if $ALT already have some insights about EMA advice).
1 · Reply
LeaperM75
LeaperM75 Feb. 4 at 3:32 AM
$ALT Full Seeking Alpha ALT article 2/3/26. See comments for full slides.
2 · Reply
Chucho64
Chucho64 Feb. 4 at 3:23 AM
$ALT Will they be friends with Bio Rich?🤔🙄🤡🤔🙄🤡
3 · Reply
Chucho64
Chucho64 Feb. 4 at 3:22 AM
$ALT Many new people are writing here, and if you check their history, they've never spoken or written about ALT before.🤔🤡🤔🤡🤔🤡🤔
0 · Reply